SRR8613703
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613779 | — | D | 0.907 |
| 2 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.902 |
| 3 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.900 |
| 4 | 544dbca2-f436-4cb7-9e11-572ead91d28d | — | — | 0.899 |
| 5 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.893 |
| 6 | SRR8518453 | — | F | 0.889 |
| 7 | s0122297 | — | — | 0.888 |
| 8 | TCGA-P6-A5OF-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.887 |
| 9 | 20040084.LumA | — | A | 0.882 |
| 10 | SRR11296795 | — | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.590 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| MYOGENESIS | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.440 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.440 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.390 | Inavolisib | — uncovered |
| HYPOXIA | 0.370 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.340 | Temsirolimus | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |